Alain H. Rook

发表

Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12.

G. Trinchieri, F. Fox, M. Kubin, 1997, The Journal of investigative dermatology.

Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.

S. Lessin, A. Rook, E. K. Yoo, 2001, Journal of the American Academy of Dermatology.

IL-12 synthesis by human Langerhans cells.

G. Trinchieri, M. Kubin, S. Lessin, 1996, Journal of immunology.

Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12.

G. Trinchieri, F. Fox, M. Kubin, 1997, Journal of Investigative Dermatology.

IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.

G. Trinchieri, M. Kubin, S. Lessin, 1995, Journal of immunology.

Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression.

C. Felix, S. Lessin, A. Rook, 1998, The Journal of investigative dermatology.

Psoralen Plus UVA Induces Local IFN Production and Antitumor Responses in Cutaneous T-Cell Lymphoma.

R. Goel, Alain H. Rook, 2023, The Journal of investigative dermatology.

Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells.

G. Trinchieri, F. Fox, M. Kubin, 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4.

L. Showe, F. Fox, A. Rook, 1999, Journal of immunology.

Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma.

D. Grossman, F. Fox, A. Rook, 1998, Current opinion in oncology.

Th2 cytokine profile in cutaneous T-cell lymphoma.

S. Lessin, A. Rook, B. Vowels, 1995, The Journal of investigative dermatology.

Expression of interleukin-4 and interleukin-5 mRNA in developing cutaneous late-phase reactions.

B. Zweiman, A. Rook, B. Vowels, 1995, The Journal of allergy and clinical immunology.

Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.

P. Nowell, L. Shaw, M. Wasik, 1996, Proceedings of the National Academy of Sciences of the United States of America.

De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma.

S. Lessin, A. Rook, A. Singh, 1995, Journal of the American Academy of Dermatology.

Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens.

R. Washko, A. Rook, G. Nahass, 1999, Journal of the American Academy of Dermatology.

Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis.

D. Margolis, L. French, S. Lessin, 2001, Archives of dermatology.

Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis

T. Alcindor, K. McGinnis, M. Shapiro, 2002, Bone Marrow Transplantation.